The companies add that before HARMONi-6, there were no known Phase 3 trials in NSCLC that showed a statistically significant improvement compared to PD-(L)1 inhibitor therapy in combination with chemotherapy in a head-to-head setting. Summit Therapeutics Inc.'s SMMT partner, Akeso, Inc., released topline data from the Phase 3 HARMONi- 6/K112-306 trial on Wednesday. The trial is evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, an anti-PD-1 antibody, in combin ...